サポート ブログ Engineered Antibody Formats: A Historical Perspective

Engineered Antibody Formats: A Historical Perspective

Biointron 2024-05-08 Read time: 2 mins
BsAb Timeline.png
Timeline of innovations towards bispecific antibodies. DOI: 10.1038/s41573-019-0028-1

Modified versions of antibodies have been designed to improve certain properties or functionalities, e.g. to enhance their therapeutic or diagnostic potential.  

Monoclonal antibodies (mAbs):  

  • Two identical binding sites each recognize the same target antigen. 

  • Monoclonal antibodies revolutionized medical therapeutics in the 1980s following the development of hybridoma technology. This technology enabled the production of antibodies that were identical in their antigen recognition, thereby providing a consistent therapeutic tool in various medical applications, notably in oncology and autoimmune diseases. 

Bispecific antibodies (bsAbs):  

  • Two unique binding sites are directed at two different antigens or two different epitopes on the same antigen. 

  • Bispecific antibodies' dual-targeting feature allows them to perform complex biological tasks such as linking cancer cells to immune cells to enhance cell destruction, a function not achievable with traditional mAbs. This functionality has been leveraged in recent therapeutic approaches, particularly in cancer immunotherapy. 

Historical Milestones in Antibody Engineering 

1960s: The conceptual groundwork for bsAbs was laid. The first bispecific antibodies were described when Fabs from two polyclonal sera were re-associated into F(ab')2 molecules after reduction and reoxidation. 

1980s: The development of hybridoma technology facilitated the production of the first monoclonal Abs. 

1992: The first article demonstrating the therapeutic potential of bsAbs was published, setting the stage for future clinical applications. 

2000s: Catumaxomab and blinatumomab became the first bsAbs to receive approval for therapeutic use, validating the clinical efficacy of bsAbs in treating diseases. 

Present: Ongoing advancements in antibody engineering continue to expand the therapeutic landscape, with newer antibody formats being explored for improved efficacy and safety profiles in clinical settings and further regulatory approvals of bsAbs.

Subscribe to our ブログ

Recent ブログ

Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.

Dec 20, 2024
ブログ

Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.

Dec 20, 2024
ブログ

Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.

Dec 19, 2024
ブログ

Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.

Dec 19, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。